[Vendor] QSC vs Homopeptide on the same compound, same month — both cleared 98.5%
Numbers in the title, numbers in the post. QSC vs Homopeptide on the same compound, same month — both cleared 98.5%.
Figures up front so nobody has to dig: 98.5%.
Sent a vial to VendorInvestigate out of curiosity. Result was 98.0% against a claimed 97.5%, which is the first independent number I had seen for this compound anywhere.
The thing that surprised me was how much of the discussion here is inference rather than measurement.
I will update this if the picture changes rather than quietly leaving it up.
- QSQSC source pageQingdao Sigma Chemical Co., Ltd. · Qingdao · 95% here, rank 7 · shop at qingdaosigma.com →
- HOHomopeptide source pageHunan Aslsen Technology Co., Ltd. · Changsha · 91% here, rank 16 · shop at homopeptide.net →
nofollow and sponsored; nobody here is paid for it.best — the order this archive was captured in
What the glucagon arm is doing, as best anyone can say from public data.
GLP-1 and GIP agonism cover appetite and insulin secretion in ways that are now reasonably well characterised. Glucagon receptor agonism is the third leg and it is associated with increased energy expenditure and with effects on hepatic fat.
Mechanistically that is why this compound reads as a different proposition rather than a stronger version of a dual agonist. Clinically, the size and durability of that difference in humans is precisely what is not yet established, and anyone telling you otherwise is filling a gap with confidence.
The standing caveat, written out properly because it keeps getting compressed into a footnote.
Nothing containing this compound is approved by any regulator. Research-use-only material is not approved for human use. That is not a legal formality on this board — it is why there is so little independent data, why the escalation schedules people post are invented, and why nobody here can answer a dosing question.
What this board can usefully do is read the published trials carefully, log independent purity results, and be honest about how thin the evidence base is. Everything else belongs somewhere with a clinician in it.
Went up slowly, deliberately, because everything on this board says the escalation is where trouble lives. Uneventful so far and I am not going to pretend that is a finding.
Went up slowly, deliberately, because everything on this board says the escalation is where trouble lives.
Adding the standing caveat: none of this is approved anywhere and research material is not for human use.
the glucagon component is why the metabolic story reads differently
Adding the standing caveat: none of this is approved anywhere and research material is not for human use.
Disagree with this specific inference. A 48-week readout does not tell you the shape of the curve after it.
Kept a log specifically because there is so little published. It is one person and it is not data.
the energy-expenditure story is mechanistically interesting and clinically unproven
not approved anywhere, which is the single most important fact in this board
Increases in heart rate have been reported across this receptor class. The magnitude and clinical significance are exactly what phase 3 is powered to establish.
Left up. It reads the phase 2 paper carefully and it is honest about the intervals.
dose escalation in the trials was slow for a reason
a lot of the confident posting here is extrapolation
That reads as a titration plan for an unapproved compound. This board cannot host that and it should not want to.
Has anyone posted an independent test on this compound recently?
research-use-only material is not approved for human use, full stop
phase 2 data only, and people quote it like it is a label
Correction: TRIUMPH is the phase 3 programme. The number you are quoting is from the phase 2 readout, which is a different trial.
- 1The standing caveat, written out properly because it keeps getting…7 comments in this branch · started by u/rui_only_ro
- 2dose escalation in the trials was slow for a reason7 comments in this branch · started by u/reflux_report